Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma
Highlights
– Pembrolizumab combined with lenvatinib achieved an objective response rate (ORR) of 60% (12 of 20; 95% CI 36–81%) in patients with pleural mesothelioma who progressed after first‑line nivolumab plus ipilimumab.
– Median follow‑up was 11.9 months (IQR 10.8–15.8). Grade 3–4 treatment‑related adverse events (TRAEs) occurred in 70% of patients; common grade 3 events included hypertension (25%) and fatigue/malaise (20%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.